BlackRock, Inc. Increases Stake in Tonix Pharmaceuticals Holding Corp.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing an increased ownership in Tonix Pharmaceuticals Holding Corp. As of September 30, 2025, BlackRock, Inc. beneficially owns 680,036 shares of common stock, representing a 7.8% ownership stake. This marks an increase of 259,588 shares, or 61.74%, from the previous filing. The value of the holdings is approximately $12,662,270.32, reflecting a decrease of 16.30% in value. BlackRock, Inc. has sole voting power over 665,586 shares and sole dispositive power over all 680,036 shares. The filing indicates that the securities were acquired in the ordinary course of business and not for the purpose of influencing control of the issuer.